HOSPITAL UNIVERSITARIO RUBER
Departamento
Universitat de Barcelona
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Universitat de Barcelona (33)
2024
-
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659
-
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
European Journal of Nuclear Medicine and Molecular Imaging
-
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 65, Núm. 5, pp. 708-713
2023
-
Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors
Molecular Cancer, Vol. 22, Núm. 1
-
Clinical characterization and treatment outcomes of follicular cutaneous immune–related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study
Journal of the American Academy of Dermatology, Vol. 88, Núm. 3, pp. 718-720
-
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases
Melanoma research, Vol. 33, Núm. 2, pp. 155-158
-
Neuroimaging in infants with congenital cytomegalovirus infection and its correlation with outcome: emphasis on white matter abnormalities
Archives of Disease in Childhood: Fetal and Neonatal Edition, Vol. 109, Núm. 2, pp. 151-158
-
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
JAMA Oncology, Vol. 9, Núm. 4, pp. 490-499
2022
-
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients*
British Journal of Dermatology, Vol. 187, Núm. 6, pp. 962-969
-
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
eBioMedicine, Vol. 75
-
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
Cancer Treatment Reviews, Vol. 111
-
Sample CME manuscript submission: Response to the article by Pham et al entitled “Review BRAF inhibition and the spectrum of granulomatous reactions”
Journal of the American Academy of Dermatology
-
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study
Future oncology (London, England), Vol. 18, Núm. 33, pp. 3677-3688
2021
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871
-
Environmental exposure during pregnancy: Influence on prenatal development and early life: A comprehensive review
Fetal Diagnosis and Therapy, Vol. 48, Núm. 4, pp. 245-257
-
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
npj Breast Cancer, Vol. 7, Núm. 1
-
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT
EBioMedicine, Vol. 69
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394
-
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box
Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1875, Núm. 1
2020
-
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649